A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf ...

The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancersDana-Farber Cancer ...

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

(Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers ... and non-small cell lung cancer (NSCLC). In addition, new clinical data will be provided ...

We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance ...

The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and ...